Melbourne-based company Tocovite claims an absorption system that it has developed could improve drug delivery through the skin.
Anti-cancer treatment SIR-Spheres, designed by Sydney-based company Sirtex, has been used on a patient for the first time since it received US Food and Drug Administration (FDA) approval in March this year.
A research and development agreement with the aim of finding an effective treatment for type II diabetes has been signed in Melbourne.
Australian researchers have determined three genetic loci which are linked to heart attacks.
Australian research on sugars which stimulate stem cells to become bone tissue has resulted in a biological paste that promotes healing of fractures and breaks.
Cardiologists may be prescribing sleep disorder treatments to their patients in the next five years, according to reports from the 14th World Congress of Cardiology, held recently in Sydney.
South Australian genomics company Bionomics has expanded its portfolio of potential epilepsy drug targets with the filing of eight new patents.
Mass spectrometry is helping Melbourne researchers develop a diagnostic test for the early detection of ovarian cancer.
A device for the early detection of skin cancer has been launched by Sydney-based medical device company, Polartechnics.
Prana Biotechnology's theory for treating Alzheimer's disease with zinc-targeted drugs has won support from a paper published this week in the Proceedings of the National Academy of Science.
The US government is paying for tests of a Melbourne-developed microbicide gel on macaque monkeys.
Brisbane based Progen Industries has moved into Phase II clinical trials for their small molecule cancer drug PI-88.
Peplin Biotech has broadened its research pipeline for anti-cancer drugs that target diseases of the pancreas.
The Australian Genome Research Facility (AGRF) has played a crucial role in a major international study on the genetic causes of schizophrenia.
Biopharmaceutical research and development group Virax Holdings has announced it has finished recruiting patients to its HIV treatment trial.